Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Ketanodur 60mg modified-release tablets
0206010K0BYAAAE
|
Ketanodur | Isosorbide mononitrate | Cardiovascular System | No data available |
|
Ketanserin 20mg tablets
0205080A0AAABAB
|
Ketanserin | Ketanserin | Cardiovascular System | No data available |
|
Ketek 400mg tablets
0501050T0BBAAAA
|
Ketek | Telithromycin | Infections | No data available |
|
Ketensin 20mg tablets
0205080A0BCAAAB
|
Ketensin | Ketanserin | Cardiovascular System | No data available |
|
Ketocid 200 modified-release capsules
1001010L0BIAAAJ
|
Ketocid 200 | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoconazole 1% shampoo
1309000I0AAACAC
|
Ketoconazole (Scalp) | Ketoconazole | Skin | No data available |
|
Ketoconazole 100mg/5ml oral suspension
0502020A0AAADAD
|
Ketoconazole (Systemic) | Ketoconazole | Infections | No data available |
|
Ketoconazole 60mg/5ml oral suspension
0502020A0AAAEAE
|
Ketoconazole (Systemic) | Ketoconazole | Infections | No data available |
|
Ketoconazole 75mg/5ml oral suspension
0502020A0AAAFAF
|
Ketoconazole (Systemic) | Ketoconazole | Infections | No data available |
|
Ketopine 2% shampoo
1309000I0BFAAAA
|
Ketopine | Ketoconazole | Skin | No data available |
|
Ketoprofen 10% gel
100302010AAACAC
|
Ketoprofen (Topical) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg / Omeprazole 20mg modified-release capsules
1001010L0AAAMAM
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg capsules
1001010L0AAABAB
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 100mg/2ml solution for injection ampoules
1001010L0AAAGAG
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 150mg modified-release capsules
1001010L0AAALAL
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 200mg / Omeprazole 20mg modified-release capsules
1001010L0AAANAN
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketoprofen 50mg capsules
1001010L0AAAAAA
|
Ketoprofen (Systemic) | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketorolac 10mg tablets
1501042E0AAACAC
|
Ketorolac trometamol (Systemic) | Ketorolac trometamol | Anaesthesia | No data available |
|
Ketorolac 10mg/1ml solution for injection ampoules
1501042E0AAABAB
|
Ketorolac trometamol (Systemic) | Ketorolac trometamol | Anaesthesia | No data available |
|
Ketotard XL 200mg capsules
1001010L0BLAAAJ
|
Ketotard | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketotifen 250micrograms/5ml oral suspension
0304010AGAAAEAE
|
Ketotifen Fumarate (Systemic) | Ketotifen fumarate | Respiratory System | No data available |
|
Ketotifen 500micrograms/5ml oral solution
0304010AGAAADAD
|
Ketotifen Fumarate (Systemic) | Ketotifen fumarate | Respiratory System | No data available |
|
Ketovail 100mg modified-release capsules
1001010L0BEAAAI
|
Ketovail | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
Ketovail 200mg modified-release capsules
1001010L0BEABAJ
|
Ketovail | Ketoprofen | Musculoskeletal and Joint Diseases | No data available |
|
KetoVie 4:1 Plant-Based Protein liquid
0913181G0BCADAE
|
KetoVie ready to serve 4:1 milkshake with fibre | Ready to serve 4:1 milkshake with fibre (0913181) | Nutrition and Blood | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.